Skip to main content

Table 4 Age-adjusted and multivariable Cox regression analysis of 143 patients for overall survival (a) and disease-specific survival (b)

From: Expression of toll-like receptors in non-endemic nasopharyngeal carcinoma

 

Age-adjusted

Multivariablea

HR (95% CI)

p-value

HR (95% CI)

p-value

a) Overall survival (OS)

 Stage

  II vs. I

2.13 (0.96–4.73)

0.064 NS

  

  III vs. I

2.79 (1.30–5.95)

0.008

  

  IV vs. I

4.52 (2.12–9.64)

< 0.001

  

 Viral status

  HPV-pos vs. EBV-pos

1.62 (0.88–3.00)

0.123 NS

  

  HPV/EBV-neg vs. EBV-pos

2.67 (1.64–4.34)

< 0.001

  

 TLR1

  Mild vs. neg

0.30 (0.09–1.04)

0.057 NS

0.69 (0.18–2.70)

0.595 NS

  Strong vs. neg

0.24 (0.08–0.79)

0.018

0.48 (0.14–1.70)

0.256 NS

 TLR2 nuclear

  Mild vs. neg

0.56 (0.25–1.24)

0.151 NS

0.53 (0.23–1.19)

0.125 NS

  Strong vs. neg

0.62 (0.27–1.45)

0.271 NS

0.52 (0.21–1.30)

0.162 NS

 TLR2 cytoplasmic

  Mild vs. neg

0.62 (0.27–1.41)

0.256 NS

0.49 (0.20–1.17)

0.109 NS

  Strong vs. neg

0.70 (0.31–1.55)

0.373 NS

0.68 (0.30–1.56)

0.363 NS

 TLR4

  Mild vs. neg

1.16 (0.51–2.65)

0.727 NS

1.07 (0.46–2.50)

0.872 NS

  Moderate/strong vs. neg

1.15 (0.52–2.55)

0.731 NS

1.13 (0.50–2.56)

0.775 NS

 TLR5

  Mild vs. neg

0.75 (0.45–1.24)

0.259 NS

0.65 (0.38–1.10)

0.108 NS

  Strong vs. neg

1.37 (0.80–2.33)

0.250 NS

0.88 (0.47–1.61)

0.666 NS

 TLR7

  Mild vs. neg

0.28 (0.12–0.64)

0.003

0.37 (0.16–0.84)

0.018

  Moderate/strong vs. neg

0.49 (0.23–1.04)

0.062 NS

0.44 (0.20–0.95)

0.038

 TLR9

  Mild vs. neg

0.21 (0.07–0.60)

0.004

0.37 (0.12–1.16)

0.087 NS

  Strong vs. neg

0.32 (0.12–0.92)

0.034

0.49 (0.17–1.46)

0.199 NS

b) Disease-specific survival (DSS)

 Stage

  II vs. I

2.50 (0.68–9.14)

0.166 NS

  

  III vs. I

4.72 (1.40–15.95)

0.013

  

  IV vs. I

8.63 (2.59–28.80)

< 0.001

  

 Viral status

  HPV-pos vs. EBV-pos

1.10 (0.49–2.47)

0.822 NS

  

  HPV/EBV-neg vs. EBV-pos

2.22 (1.25–3.96)

0.007

  

 TLR1

  Mild vs. neg

0.50 (0.11–2.25)

0.369 NS

1.30 (0.26–6.57)

0.748 NS

  Strong vs. neg

0.32 (0.08–1.32)

0.113 NS

0.76 (0.17–3.43)

0.720 NS

 TLR2 nuclear

  Mild vs. neg

0.75 (0.26–2.10)

0.578 NS

0.88 (0.31–2.52)

0.811 NS

  Strong vs. neg

0.84 (0.28–2.54)

0.757 NS

1.05 (0.33–3.34)

0.937 NS

 TLR2 cytoplasmic

  Mild vs. neg

0.62 (0.23–1.65)

0.336 NS

0.69 (0.25–1.90)

0.468 NS

  Strong vs. neg

0.71 (0.28–1.84)

0.481 NS

0.89 (0.33–2.34)

0.806 NS

 TLR4

  Mild vs. neg

1.52 (0.54–4.41)

0.441 NS

1.65 (0.56–4.88)

0.368 NS

  Moderate/strong vs. neg

1.12 (0.40–3.20)

0.827 NS

1.28 (0.44–3.73)

0.652 NS

 TLR5

  Mild vs. neg

0.87 (0.47–1.61)

0.665 NS

0.81 (0.43–1.53)

0.518 NS

  Strong vs. neg

1.62 (0.85–3.06)

0.141 NS

1.34 (0.64–2.80)

0.442 NS

 TLR7

  Mild vs. neg

0.28 (0.11–0.70)

0.006

0.39 (0.15–0.98)

0.046

  Moderate/strong vs. neg

0.47 (0.21–1.05)

0.067 NS

0.47 (0.21–1.09)

0.079 NS

 TLR9

  Mild vs. neg

0.27 (0.08–0.93)

0.038

0.54 (0.15–1.98)

0.351 NS

  Strong vs. neg

0.39 (0.12–1.29)

0.123 NS

0.70 (0.20–2.43)

0.576 NS

  1. a Adjusted for age, gender, stage, and viral status